Literature DB >> 16767220

Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice.

Xiaoling Xu1, Shogo Kobayashi, Wenhui Qiao, Cuiling Li, Cuiying Xiao, Svetlana Radaeva, Bangyan Stiles, Rui-Hong Wang, Nobuya Ohara, Tadashi Yoshino, Derek LeRoith, Michael S Torbenson, Gregory J Gores, Hong Wu, Bin Gao, Chu-Xia Deng.   

Abstract

Cholangiocellular carcinoma (CC), the second most common primary liver cancer, is associated with a poor prognosis. It has been shown that CCs harbor alterations of a number of tumor-suppressor genes and oncogenes, yet key regulators for tumorigenesis remain unknown. Here we have generated a mouse model that develops CC with high penetrance using liver-specific targeted disruption of tumor suppressors SMAD4 and PTEN. In the absence of SMAD4 and PTEN, hyperplastic foci emerge exclusively from bile ducts of mutant mice at 2 months of age and continue to grow, leading to tumor formation in all animals at 4-7 months of age. We show that CC formation follows a multistep progression of histopathological changes that are associated with significant alterations, including increased levels of phosphorylated AKT, FOXO1, GSK-3beta, mTOR, and ERK and increased nuclear levels of cyclin D1. We further demonstrate that SMAD4 and PTEN regulate each other through a novel feedback mechanism to maintain an expression balance and synergistically repress CC formation. Finally, our analysis of human CC detected PTEN inactivation in a majority of p-AKT-positive CCs, while about half also lost SMAD4 expression. These findings elucidate the relationship between SMAD4 and PTEN and extend our understanding of CC formation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16767220      PMCID: PMC1474816          DOI: 10.1172/JCI27282

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  49 in total

1.  Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998.

Authors:  S D Taylor-Robinson; M B Toledano; S Arora; T J Keegan; S Hargreaves; A Beck; S A Khan; P Elliott; H C Thomas
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

2.  Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice.

Authors:  X Xu; S G Brodie; X Yang; Y H Im; W T Parks; L Chen; Y X Zhou; M Weinstein; S J Kim; C X Deng
Journal:  Oncogene       Date:  2000-04-06       Impact factor: 9.867

3.  Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma.

Authors:  K Sugimachi; K Taguchi; S Aishima; S Tanaka; M Shimada; K Kajiyama; K Sugimachi; M Tsuneyoshi
Journal:  Mod Pathol       Date:  2001-09       Impact factor: 7.842

4.  Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo.

Authors:  M Groszer; R Erickson; D D Scripture-Adams; R Lesche; A Trumpp; J A Zack; H I Kornblum; X Liu; H Wu
Journal:  Science       Date:  2001-11-01       Impact factor: 47.728

5.  Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes.

Authors:  Satdarshan P S Monga; Wendy M Mars; Peter Pediaditakis; Aaron Bell; Karen Mulé; William C Bowen; Xue Wang; Reza Zarnegar; George K Michalopoulos
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

6.  Generation of Smad4/Dpc4 conditional knockout mice.

Authors:  Xiao Yang; Cuiling Li; Pedro-Luis Herrera; Chu-Xia Deng
Journal:  Genesis       Date:  2002-02       Impact factor: 2.487

7.  Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma.

Authors:  Yasuhiro Ito; Tsutomu Takeda; Yo Sasaki; Masato Sakon; Terumasa Yamada; Shingo Ishiguro; Shingi Imaoka; Masahiko Tsujimoto; Morito Monden; Nariaki Matsuura
Journal:  Liver       Date:  2002-04

8.  Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma.

Authors:  K Kiguchi; S Carbajal; K Chan; L Beltrán; L Ruffino; J Shen; T Matsumoto; N Yoshimi; J DiGiovanni
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

Review 9.  Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment.

Authors:  Kunio Okuda; Yasuni Nakanuma; Masaru Miyazaki
Journal:  J Gastroenterol Hepatol       Date:  2002-10       Impact factor: 4.029

10.  Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1.

Authors:  M P A Ebert; G Fei; L Schandl; C Mawrin; K Dietzmann; P Herrera; H Friess; T M Gress; P Malfertheiner
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

View more
  97 in total

1.  MicroRNAs control hepatocyte proliferation during liver regeneration.

Authors:  Guisheng Song; Amar Deep Sharma; Garrett R Roll; Raymond Ng; Andrew Y Lee; Robert H Blelloch; Niels M Frandsen; Holger Willenbring
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

2.  Prostate apoptosis response-4 is expressed in normal cholangiocytes, is down-regulated in human cholangiocarcinoma, and promotes apoptosis of neoplastic cholangiocytes when induced pharmacologically.

Authors:  Antonio Franchitto; Alessia Torrice; Rossella Semeraro; Cristina Napoli; Gennaro Nuzzo; Felice Giuliante; Gianfranco Alpini; Guido Carpino; Pasquale Bartolomeo Berloco; Luciano Izzo; Antonio Bolognese; Paolo Onori; Anastasia Renzi; Alfredo Cantafora; Eugenio Gaudio; Domenico Alvaro
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

3.  Adaptive basal phosphorylation of eIF2α is responsible for resistance to cellular stress-induced cell death in Pten-null hepatocytes.

Authors:  Ni Zeng; Yang Li; Lina He; Xiaoling Xu; Vivian Galicia; Chuxia Deng; Bangyan L Stiles
Journal:  Mol Cancer Res       Date:  2011-10-18       Impact factor: 5.852

4.  Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism.

Authors:  Gabriel Frampton; Pietro Invernizzi; Francesca Bernuzzi; Hae Yong Pae; Matthew Quinn; Darijana Horvat; Cheryl Galindo; Li Huang; Matthew McMillin; Brandon Cooper; Lorenza Rimassa; Sharon DeMorrow
Journal:  Gut       Date:  2011-11-07       Impact factor: 23.059

Review 5.  Comparative analysis of the liver and plasma proteomes as a novel and powerful strategy for hepatocellular carcinoma biomarker discovery.

Authors:  Laura Beretta
Journal:  Cancer Lett       Date:  2009-02-15       Impact factor: 8.679

6.  A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Hepat Oncol       Date:  2014-01-01

7.  Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands.

Authors:  Hayato Nakagawa; Nobumi Suzuki; Yoshihiro Hirata; Yohko Hikiba; Yoku Hayakawa; Hiroto Kinoshita; Sozaburo Ihara; Koji Uchino; Yuji Nishikawa; Hideaki Ijichi; Motoyuki Otsuka; Junichi Arita; Yoshihiro Sakamoto; Kiyoshi Hasegawa; Norihiro Kokudo; Keisuke Tateishi; Kazuhiko Koike
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

8.  Progranulin: a novel regulator of gastrointestinal cancer progression.

Authors:  Sharon Demorrow
Journal:  Transl Gastrointest Cancer       Date:  2013-07

9.  The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma.

Authors:  Joon-Yong Chung; Seung-Mo Hong; Byeong Yeob Choi; Hyungjun Cho; Eunsil Yu; Stephen M Hewitt
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

10.  Pathobiology of biliary epithelia and cholangiocarcinoma: proceedings of the Henry M. and Lillian Stratton Basic Research Single-Topic Conference.

Authors:  Alphonse E Sirica; Michael H Nathanson; Gregory J Gores; Nicholas F Larusso
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.